Completed OBSERVATIONAL NCT01109238

A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Sponsor: Giselle Sholler

Conditions Refractory Neuroblastoma Relapsed Neuroblastoma

Updated 9 times since 2017 Last updated: Aug 2, 2024 Started: Apr 30, 2010 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Refractory Neuroblastoma and Relapsed Neuroblastoma and is currently completed. Giselle Sholler leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Oct 2023 — Jul 2024 [monthly]

Completed
May 2022 — Oct 2023 [monthly]

Completed
Jan 2021 — May 2022 [monthly]

Completed

▶ Show 4 earlier versions

Dec 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Dec 2020 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Giselle Sholler
Van Andel Research Institute

Data source: Milton S. Hershey Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Burlington, United States